The Clinical Trajectory of NYHA Functional Class I Patients With Obstructive Hypertrophic Cardiomyopathy
Ahluwalia M, Liu J, Olivotto I, Parikh V, Ashley E, Michels M, Ingles J, Lampert R, Stendahl J, Colan S, Abrams D, Pereira A, Rossano J, Ryan T, Owens A, Ware J, Saberi S, Helms A, Day S, Claggett B, Ho C, Lakdawala N. The Clinical Trajectory of NYHA Functional Class I Patients With Obstructive Hypertrophic Cardiomyopathy. JACC Heart Failure 2024 PMID: 39520446, DOI: 10.1016/j.jchf.2024.09.008.Peer-Reviewed Original ResearchObstructive hypertrophic cardiomyopathyClass I patientsFunctional class II patientsNYHA functional class IClass II patientsFunctional class II patientsII patientsHypertrophic cardiomyopathyFollow-upLeft ventricular outflow tract obstructionVentricular outflow tract obstructionNYHA functional class IILeft ventricular ejection fractionRates of clinical outcomesClass INatural historyRestricted cubic spline modelsSeptal reduction therapyOutflow tract obstructionFunctional class IIVentricular ejection fractionComposite event rateCubic spline modelsCox proportional hazardsLong‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study
Masri A, Lester S, Stendahl J, Hegde S, Sehnert A, Balaratnam G, Shah A, Fox S, Wang A. Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study. Journal Of The American Heart Association 2024, 13: e030607. PMID: 38591260, PMCID: PMC11262496, DOI: 10.1161/jaha.123.030607.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyKansas City Cardiomyopathy Questionnaire–Overall Summary scoreSymptomatic obstructive hypertrophic cardiomyopathyOutflow tract gradientHypertrophic cardiomyopathyNew York Heart Association class improvementLeft ventricular outflow tract gradientTreatment-emergent adverse eventsSerum NT-proBNP levelsLeft ventricular ejection fractionEffect of mavacamtenIndividual dose titrationNT-proBNP levelsVentricular ejection fractionSerum NT-proBNPSummary scoreLong-term safetyLonger-term treatmentDose titrationEjection fractionNT-proBNPB-blockersReduced doseAdverse eventsInterim results